ClinicalTrials.gg
Active, not recruitingNCT06686654Updated Dec 11, 2025

Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

A Phase 1/2 interventional study of Investigational hMPV/RSV vaccine and Investigational hMPV vaccine (monovalent) in Human Metapneumovirus Immunization and Respiratory Syncytial Virus Immunization, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 24 sites in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,530
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Respiratory Syncytial Virus Infections by Sanofi — none open to participants now, 2 under way, none of them phase 3. Respiratory Syncytial Virus Infections · Sanofi.

Enrollment
2nd of 14
1,530 · median 310
Started
2024
with 4 others
Phase 1/2
5 of 15
none open now
Registered
13th of 15
by date

Among the 15 studies in Respiratory Syncytial Virus Infections by Sanofi, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 1/2, and was the 13th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

None of the 15 studies in Respiratory Syncytial Virus Infections by Sanofi is open now. The open studies under Respiratory Syncytial Virus Infections, anywhere →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Respiratory Syncytial Virus Infections by Sanofi as a file.
02

Study summary

The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older.

The study will also evaluate the safety and immunogenicity of a booster vaccination using a bivalent hMPV/RSV mRNA vaccine candidate (hereafter referred to as RSV+hMPV mRNA vaccine candidate).

Overall, the study is designed to address the following goals:

  • Assess the safety profile of the candidate formulations.
  • Describe the immunogenicity profile of the candidate formulations.
  • Select the vaccine formulations (dose) for future development.
  • Assess the safety and immunogenicity of a booster vaccination with the RSV + hMPV mRNA vaccine candidate administered 12 months after primary vaccination with a licensed RSV vaccine.

The study duration is as follows:

-Six months each for the Sentinel and Main Cohorts; up to 12 months for the Expansion Cohort, and 6 additional months for the Booster Cohort

Treatment duration:

  • Stage 1 Sentinel Cohort: 1 intra-muscular (IM) injection. Participants will be followed for 6 months post vaccination
  • Stage 1 Main Cohort: 1 IM injection. Participants will be followed for 6 months post vaccination
  • Stage 2 Expansion Cohort: 1 IM injection. Participants in the licensed RSV vaccine arm will be followed for 12 months post-vaccination; the remainder of the participants will be followed up to 8 months post-vaccination
  • Stage 2 Booster Cohort: 1 IM injection 12 months post-primary vaccination. Participants will be followed for 6 months post-booster vaccination
03

Conditions studied

  • Human Metapneumovirus Immunization
  • Respiratory Syncytial Virus Immunization

Keywords

  • hMPV
  • RSV
  • respiratory syncytial virus infection
  • human metapneumovirus infection
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 60 years or older on the day of inclusion
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and is of non-. To be considered of non-childbearing potential, a female must be for at least 1 year or surgically sterile

Exclusion criteria

Exclusion Criteria:

  • Any screening laboratory parameter with laboratory abnormality > Grade 1 deemed by the investigator
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). Of note, persons living with stable (HIV) are not excluded
  • Known systemic to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of an mRNA vaccine
  • History of RSV and/or hMPV-associated illness, diagnosed serologically or microbiologically in the last 12 months
  • Previous history of myocarditis, pericarditis, and/or myopericarditis
  • Screening that is consistent with possible myocarditis, pericarditis, and/or myopericarditis or, in the opinion of the investigator, demonstrates clinically relevant abnormalities that may affect participant safety or study results
  • Laboratory-confirmed thrombocytopenia, contraindicating IM injection, based on investigator's judgment
  • Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection, based on investigator's judgment
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Receipt of any vaccine other than mRNA vaccine in the 28 days preceding any study intervention administration or planned receipt of any vaccine other than mRNA vaccine in the 28 days following any study intervention administration
  • Receipt of any mRNA vaccine in the 60 days preceding any study intervention administration or planned receipt of any mRNA vaccine in the 60 days following any study intervention administration
  • Previous vaccination against RSV and/or hMPV (with a licensed or vaccine either as a monovalent vaccine or any combination of the antigens)
  • Receipt of immune globulins, blood, or blood-derived products in the past 3 months

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,530 participants (actual)

Study arms

  • Experimental
    Group A Stage 1 Sentinel Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation A

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group B Stage 1 Sentinel Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation B

    Biological: Investigational hMPV/RSV vaccine

  • Placebo comparator
    Group C Stage 1 Sentinel Cohort

    1 IM injection of placebo

    Biological: Placebo

  • Experimental
    Group 1 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation C

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 2 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation D

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 3 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation E

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 4 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation F

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 5 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation G

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 6 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation A

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 7 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation B

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 8 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation H

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 9 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation I

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 10 Stage 1 Main Cohort

    1 IM injection of investigational hMPV/RSV vaccine formulation J

    Biological: Investigational hMPV/RSV vaccine

  • Placebo comparator
    Group 11 Stage 1 Main Cohort

    1 IM injection of placebo

    Biological: Placebo

  • Experimental
    Group X Stage 2 Expansion Cohort

    1 IM injection of selected investigational hMPV/RSV vaccine formulation from Group 1-9 of Stage 1 Main Cohort

    Biological: Investigational hMPV/RSV vaccine

  • Experimental
    Group 12 Stage 2 Expansion Cohort

    1 IM injection of investigational RSV monovalent vaccine

    Biological: Investigational RSV vaccine (monovalent)

  • Experimental
    Group 13 Stage 2 Expansion Cohort

    1 IM injection of investigational hMPV monovalent vaccine

    Biological: Investigational hMPV vaccine (monovalent)

  • Experimental
    Group 14 Stage 2 Expansion Cohort

    1 IM injection of licensed RSV vaccine

    Biological: Licensed RSV Vaccine

  • Experimental
    Group 15 Stage 2 Booster Cohort

    1 IM injection of investigational RSV + hMPV vaccine formulation administered to participants from Group 14 of Expansion Cohort

    Biological: Investigational hMPV/RSV vaccine · Biological: Investigational RSV+hMPV vaccine

Interventions

  • BiologicalInvestigational hMPV/RSV vaccine

    Investigational hMPV/RSV vaccine administered intramuscularly

  • BiologicalInvestigational hMPV vaccine (monovalent)

    Investigational hMPV vaccine (monovalent) administered intramuscularly

  • BiologicalInvestigational RSV vaccine (monovalent)

    Investigational RSV vaccine (monovalent) administered intramuscularly

  • BiologicalLicensed RSV Vaccine

    Licensed RSV vaccine administered intramuscularly

  • BiologicalPlacebo

    Placebo administered intramuscularly

  • BiologicalInvestigational RSV+hMPV vaccine

    Investigational RSV+hMPV vaccine administered intramuscularly

06

What researchers measure

Primary outcomes

  1. Presence of unsolicited immediate systemic adverse events (AEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)

    Number of participants reporting immediate unsolicited systemic AEs

    Time frame: Within 30 minutes after primary and booster vaccinations

  2. Presence of solicited injection site and systemic reactions (Stage 1 and Stage 2 Expansion and Booster Cohorts)

    Number of participants reporting solicited injection site and systemic reactions

    Time frame: Up to 7 days after primary and booster vaccinations

  3. Presence of unsolicited AEs (Stage 1 and Stage 2 Expansion and Booster Cohorts)

    Number of participants reporting unsolicited AEs

    Time frame: Up to 28 days after primary and booster vaccinations

  4. Presence of medically attended AEs (MAAEs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)

    Number of participants reporting MAAEs

    Time frame: Up to 6 months after primary and booster vaccinations

  5. Presence of serious AEs (SAEs) and AEs of special interest (AESIs) (Stage 1 and Stage 2 Expansion and Booster Cohorts)

    Number of participants reporting SAEs and AESIs

    Time frame: Up to 6 months after primary and booster vaccinations

  6. Presence of related SAEs, related AESIs, and fatal SAEs (regardless of causality) (Stage 1 and Stage 2 Expansion and Booster Cohorts)

    Number of participants reporting related SAEs, related AESIs, and fatal SAEs

    Time frame: Throughout the duration of the study (up to approximately 24 months)

  7. Presence of out-of-range biological test results (Stage 1)

    Number of participants with out-of-range biological tests

    Time frame: Up to 7 days after primary vaccination

  8. Presence of out-of-range biological test results (Stage 2 Booster Cohort)

    Number of participants with out-of-range biological tests

    Time frame: Up to 7 days after booster vaccination

  9. hMPV A serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main Cohorts

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)

  10. hMPV B serum neutralizing antibodies (nAb) titers in Stage 1 Sentinel and Main Cohorts

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01) and 28 days post-primary vaccination (Day 29)

  11. RSV A serum nAb titers in Stage 1 Sentinel and Main Cohorts

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)

  12. RSV B serum nAb titers in Stage 1 Sentinel and Main Cohorts

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At pre vaccination (D01) and 28 days post-primary vaccination (D29)

  13. hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)

  14. hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)

  15. RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)

  16. RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV/RSV vaccine candidate (Day 29)

  17. hMPV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)

  18. hMPV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the hMPV standalone vaccine (Day 29)

  19. RSV A serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)

  20. RSV B serum neutralizing antibodies (nAb) titers in Stage 2 Expansion Chort

    nAb titers expressed as geometric mean titers (GMTs)

    Time frame: At (Day 01) pre-vaccination and 28 days after the injection of the RSV standalone vaccine (Day 29)

Secondary outcomes

  1. hMPV serum anti-F immunoglobulin G (IgG) antibody (Ab) titers (Stage 1)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01) and 28 days (D29) post-primary vaccination

  2. RSV serum anti-F IgG Ab titers (Stage 1)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01) and 28 days (D29) post-primary vaccination

  3. hMPV A serum nAb titers (Stage 2 Expansion Cohort)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination

  4. hMPV B serum nAb titers (Stage 2 Expansion Cohort)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination

  5. hMPV A serum anti-F IgG Ab titers (Stage 2 Expansion Cohort)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination

  6. RSV A serum nAb titers (Stage 2 Expansion Cohort)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination

  7. RSV B serum nAb titers (Stage 2 Expansion Cohort)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination

  8. RSV serum anti-F IgG Ab titers (Stage 2 Expansion Cohort)

    Ab titers expressed as geometric mean titers (GMTs)

    Time frame: At pre-vaccination (Day 01), 28 days (D29), and 3 and 6 months post-primary vaccination

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.

Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 26 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 13, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Jan 18, 2027
CompletionEst.
Jan 18, 2027
Last update
Dec 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06686654
Responsible party
Sponsor
First posted
Nov 13, 2024
Start date
Nov 11, 2024
Primary completion
Jan 18, 2027 (estimated)
Completion
Jan 18, 2027 (estimated)
Last update
Dec 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion